“Not unusual in any respect”: AstraZeneca pauses COVID-19 vaccine trial

A double-masked health care worker jabs a needle into the arm of a seated woman in a mask.

Enlarge / A volunteer receives an injection of AZD1222 from a medical employee throughout the nation’s first human scientific trial for a possible vaccine towards COVID-19 on the Baragwanath Hospital on June 28, 2020, in Soweto, South Africa. It’s reported that Africa’s first COVID-19 vaccine trial started on June 24 in South Africa. (credit score: Getty Pictures | Felix Dlangamandla)

With the coronavirus disaster gripping the globe, all eyes are on each bump and dip on the trail to the pandemic’s finish. So, in fact, information that researchers triggered a typical pause to the scientific trials of a number one COVID-19 vaccine candidate made swift and alarming headlines late Tuesday.

The worldwide part III trials for the vaccine AZD1222 (previously ChAdOx1)—developed by the College of Oxford and pharmaceutical big AstraZeneca—have been placed on a “non permanent” and “voluntary” pause for a “normal overview course of,” AstraZeneca mentioned in an announcement Wednesday.

In accordance the corporate, the pause was triggered by a “probably unexplained sickness” in one in every of 1000’s of individuals concerned in its trials. Per normal protocol, researchers should pause the trial to analyze whether or not the sickness is said to publicity to the experimental vaccine or not.

Learn 15 remaining paragraphs | Feedback

Related Posts

Leave a Reply

Your email address will not be published.